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ABSTRACT
Three decades of research have established the
CCCTC-binding factor (CTCF) as a ubiquitously ex-
pressed chromatin organizing factor and master reg-
ulator of gene expression. A new role for CTCF
as a regulator of alternative splicing (AS) has now
emerged. CTCF has been directly and indirectly
linked to the modulation of AS at the individual
transcript and at the transcriptome-wide level. The
emerging role of CTCF-mediated regulation of AS
involves diverse mechanisms; including transcrip-
tional elongation, DNA methylation, chromatin ar-
chitecture, histone modifications, and regulation
of splicing factor expression and assembly. CTCF
thereby appears to not only co-ordinate gene expres-
sion regulation but contributes to the modulation of
transcriptomic complexity. In this review, we high-
light previous discoveries regarding the role of CTCF
in AS. In addition, we summarize detailed mecha-
nisms by which CTCF mediates AS regulation. We
propose opportunities for further research designed
to examine the possible fate of CTCF-mediated al-
ternatively spliced genes and associated biological
consequences. CTCF has been widely acknowledged
as the ‘master weaver of the genome’. Given its mul-
tiple connections, further characterization of CTCF’s
emerging role in splicing regulation might extend
its functional repertoire towards a ‘conductor of the
splicing orchestra’.
INTRODUCTION
CTCF – an old player
CCCTC-binding factor (CTCF) was first identified as a
nuclear DNA-binding protein, which negatively regulates
chicken c-myc expression by interacting with three regularly
spaced repeats of the CCCTC DNA motif (1). Since then,
considerable attention has been focused on CTCF leading
to pivotal discoveries related to its structure, binding ac-
tivities and functions. CTCF is a multivalent 11-zinc fin-
ger DNA-binding protein that is ubiquitously expressed in
most tissues of vertebrate species (1–4). Combinatorial us-
age of CTCF zinc fingers (4,5) allows its binding to tens
of thousands of conserved DNA sites as revealed by chro-
matin immunoprecipitation sequencing (ChIP-seq) exper-
iments (6–8). More than 30% and 50% of these binding
sites are located in intronic and intergenic regions, respec-
tively. These sites are mostly ubiquitous; however, cell-type-
specific CTCF binding is observed (6–8). Ubiquitous CTCF
target sites are predominantly localized within intergenic
regions and are highly conserved compared to cell-type-
specific ones, which are mostly located within introns (8).
CTCF has also been characterized as an RNA-binding
protein and these interactions are essential for facilitat-
ing CTCF-mediated chromatin architecture (9–13). Such
interactions are involved in some CTCF activities includ-
ing CTCF dimerization, distal genomic binding sites, chro-
matin looping and gene regulation (9–12). Indeed, locus- or
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transcript-specific functions for CTCF-RNA interactions
have been clearly demonstrated (9,13,14). CTCF can also
undergo multiple post-translational modifications which
could affect interactions with binding partners. These inter-
actors include transcription factors, chromatin remodelers,
methylation regulators, histone modifiers and splicing fac-
tors (reviewed in (15–17)).
The complexity of CTCF interactions is further ex-
panded by the ability of CTCF to homodimerize and
mediate contacts with multiple distal intra- and inter-
chromosomal target sites across the genome. Such interac-
tions can facilitate genome folding into topologically as-
sociating domains (TADs) and chromatin loops, encom-
passing those interaction domains (18–21). This allows
CTCF to coordinate chromatin and genome architecture,
which reinforce CTCF’s eminence as ‘the master weaver
of the genome’ (22). Chromatin looping occurs when a
DNA-bound CTCF molecule interacts with another CTCF
molecule located at a proximal or distal genomic site
(21,23). These CTCF–CTCF interactions mostly initiate
chromatin loops when the CTCF-bound sites are in a con-
vergent (i.e. forward and reverse) orientation (23,24) rather
than divergent orientation, which has been mostly observed
at non-looped TAD boundaries (20,24). CTCF also co-
ordinates chromatin architecture in concert with the co-
hesin complex to help define and stabilize chromatin loops.
While CTCF associates with over half of the cohesin bind-
ing sites genome-wide, both CTCF and cohesin also have
their own specific binding sites and independent roles in co-
ordinating chromatin organization (25–28).
Given its unique role in higher-order chromatin architec-
ture and the multiplicity and specificity of its binding sites,
CTCF is able to regulate diverse molecular and epigenetic
functions, summarized herein. CTCF is a unique regulator
of gene expression, which can function as a transcriptional
repressor and activator as well as a chromatin insulator, the
latter occurring through interference of the contact between
enhancers/silencers and promoters (5,22). Furthermore, it
epigenetically regulates gene expression through gene im-
printing, X-chromosome inactivation, and by preserving
methylation-free regions throughout the genome (15,29).
Moreover, CTCF-mediated chromatin looping modulates
gene expression by bringing genomic loci into spatial prox-
imity (30–32).
Compelling evidence has linked CTCF to modulation of
alternative splicing (AS) at both the individual transcript
and transcriptome-wide level (33–46). AS is a complex bi-
ological process, which affects over 95% of human multi-
exonic genes and enriches transcriptome and protein diver-
sity by facilitating the production of multiple mRNA and
protein isoforms from individual genes (47,48). There are
four major forms of AS including exon skipping, mutually
exclusive exons, alternative use of 5′ or 3′ splice sites and
intron retention. With more than 40% prevalence, the most
common form of AS is exon skipping, which involves the ex-
clusion of one or more exons from the mature mRNA tran-
script. Splicing can occur at a site alternative to the canon-
ical splice site, depending on whether the new splice site re-
places the canonical donor or acceptor site. Mutually exclu-
sive exons are exons from the same gene that can be differ-
entially included in the spliced gene transcript, i.e. they are
rarely found together in the same mature mRNA. Finally,
intron retention is a process by which an intron is not ex-
cised from the pre-mRNA and therefore retained in the ma-
ture mRNA transcript, often leading to nonsense-mediated
mRNA decay (47,48).
CTCF’s involvement with AS, identified over the past
decade, has expanded the list of mechanisms by which
CTCF can regulate gene expression and transcriptomic
complexity (33–46); however, its direct impact on biological
functions has not been fully elucidated. Herein, we highlight
the CTCF-mediated mechanisms linked to AS regulation.
While the majority of these mechanisms have not been fully
characterized, we emphasize the extent to which CTCF has
been experimentally verified as a regulator of AS. Further-
more, we track the putative roles of CTCF in modulating
AS, placing them in context of the regulatory mechanisms
governing the transcriptional and splicing machinery. This
review provides a roadmap toward understanding and fur-
ther studying the under-recognized role of CTCF in AS reg-
ulation.
NEW TRICKS: CTCF IN ALTERNATIVE SPLICING
REGULATION
It is widely accepted that AS re-configures the transcrip-
tome and proteome to facilitate certain biological processes.
Perturbations to this highly calibrated process can cause
diseases such as Hutchinson-Gilford Progeria syndrome,
Duchenne muscular dystrophy, melanoma and breast can-
cer (49,50). Thus, maintaining tight control of AS requires a
complex regulatory network integrating co-transcriptional,
genomic and epigenetic factors such as transcriptional elon-
gation, DNA methylation, chromatin architecture, histone
modifications, and splicing factor expression and assembly
(51,52). Over the past decade, CTCF has been character-
ized as a direct and indirect modulator of AS decisions. This
function is achieved through various mechanisms involving
multiple factors including co-transcriptional regulation, ge-
nomic features and epigenetic factors (33–46), as summa-
rized (Figure 1) and discussed henceforth.
CO-TRANSCRIPTIONAL REGULATION
RNA polymerase II elongation and archetypal CD45 locus
RNA polymerase II (RNAPII) elongation is fundamental
to transcription and constitutive splicing processes, which
require an optimal RNAPII elongation rate for producing
canonical mature mRNA transcripts. This means that slow-
ing or accelerating transcription elongation can both in-
hibit or enhance splice site recognition depending on ad-
ditional factors. Alteration of the elongation rate influences
inclusion of exons or introns particularly those having weak
splice sites and short flanking introns (53–56). In a pivotal
discovery, Shukla et al. revealed the first direct link ‘road-
block model’ between CTCF and AS regulation involv-
ing RNAPII elongation and methylation of CTCF binding
sites. Binding of CTCF to CD45 exon 5 impedes RNAPII
elongation which allows the spliceosome to assemble at the
weak upstream splice site and eventually leads to the inclu-
sion of exon 5 in human Burkitt lymphoma B cells (33) (Fig-
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Figure 1. Mechanisms of CTCF-mediated regulation of alternative splicing. CTCF has been linked to key determinants of AS regulation which can be
broadly categorized into co-transcriptional, genomic and epigenetic mechanisms. During co-transcriptional regulation, CTCF-mediated AS is regulated
by stalling RNAPII transcriptional elongation (33–35,42), controlling DNA methylation (60–62) and recruitment of splicing factors (42,58,66). While the
co-transcriptional factors have been mostly experimentally verified, the genomic and epigenetic regulatory roles of CTCF in modulating AS are putative.
These involve localization of CTCF binding sites proximal to splice sites (33–38,40–42,44), chromatin architecture (35,36), nucleosome enrichment (7,85–
87), histone modification (35,46) and regulation of CTCF binding via DNA methylation patterns (33,34,36,38,40,41).
of multiple isoforms, which have been tightly linked to lym-
phocyte development (57). This putative new role for CTCF
in the regulation of lymphocyte development demands fur-
ther study.
The decision for CTCF-mediated CD45 exon 5 inclusion
is tightly regulated by the methylation status of a CTCF
binding site in cis. CTCF depletion or loss of CTCF bind-
ing due to methylation within its cognate binding site sup-
ports faster RNAPII elongation and subsequently exon ex-
clusion (33,34). While 5-methylcytosine (5mC) evicts CTCF
and promotes exon exclusion, DNMT1 depletion decreases
5mC levels at exon 5 and promotes CTCF binding and
exon inclusion (33). In addition, members of the TET (Ten-
eleven translocation) family of methylcytosine dioxygenases
(TET1 and TET2) oxidize 5mC to 5-hydroxymethylcytosine
(5hmC) and its downstream oxidative intermediates. This
can subsequently promote CTCF binding and exon inclu-
sion, which is reversed by depleting TET1 and TET2 ex-
pression (34).
In line with this context-dependent regulatory mecha-
nism, a global correlation between CTCF, RNAPII occu-
pancy and exon inclusion was detected when CTCF bind-
ing occurs within ∼1 kb downstream of alternatively spliced
exons in BJAB and BL41 cells (33). This has been indepen-
dently supported by a stronger association between CTCF
and RNAPII sites mostly downstream (∼0.6 kb) of differ-
entially included exons in MCF7 breast cancer cells com-
pared to non-tumorigenic MCF10A mammary cells (46).
Furthermore, there were global reciprocal exchanges of
5mC and 5hmC at CTCF binding sites downstream (∼1.5
kb) of differentially alternatively spliced exons in naive and
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Figure 2. CTCF-mediated co-transcriptional regulation of alternative splicing. Schematic representation of co-transcriptional mechanisms by which CTCF
modulates AS. (A) The ‘roadblock’ mechanism involves altering RNAPII elongation rate in a methylation-dependent manner (33,34). (B) CTCF regulation
of DNA methylation via activation of PARP1 and PARylation (60,61), which are also involved in other AS-related regulatory activities (66–69). (C)
Splicing factor recruitment might also take part in CTCF-mediated AS regulation through direct interaction with RNA binding proteins (42,58,70) or
other transcription factors involved in AS such as PARP1 (66), MeCP2 (38), YB-1 (108,109) and HP1 (46,124,127). SF3B1 and SRSF3 are examples of
RNA-binding proteins.
stream exon exclusion and inclusion, respectively. Neverthe-
less, the highest enrichment of CTCF binding was observed
upstream of alternatively spliced exons (34).
Beyond the roadblock model
The ‘roadblock’ model describes the phenomenon of
CTCF-mediated RNAPII elongation stalling downstream
of included exons (33). However, this role does not seem
applicable to CTCF binding sites that are highly enriched
upstream of alternatively spliced exons (34). In addition, it
also does not fully explain how CTCF occupancy exerts its
effects in an upstream or downstream direction. Moreover,
the optimal distance between a CTCF binding site and the
proximal alternatively spliced exon where RNAPII accumu-
lation occurs remains elusive.
The association of CTCF binding with RNAPII stalling
at specific sites has been previously observed genome-wide
in multiple cell lines (58), particularly at CTCF sites located
immediately downstream to promoters of specific genes (59)
including the p53 target genes PUMA and p21 (35). Within
these promoters, a higher RNAPII pausing index was as-
sociated with more proximal CTCF binding sites (59). In-
terestingly, CTCF-mediated RNAPII stalling was also de-
tected at sites where CTCF binds upstream to promoters
(59), which is consistent with Marina et al. (34). Given that
RNAPII elongation is sterically hindered by CTCF bound
at downstream regions, alternative mechanism(s) regulating
CTCF-mediated RNAPII pausing at upstream sites could
be involved. For instance, chromatin architecture influences
splicing decisions via modulation of RNAPII elongation
rate and recruitment of splicing factors (reviewed in (56),
more details provided in GENOMIC FEATURES section).
CTCF’s interplay with other factors
As a master regulator of gene expression, CTCF has the
capacity to regulate the expression of numerous epige-
netic modulators as well as genes involved in the transcrip-
tional and splicing machinery. These include splicing fac-
tors, methylation regulators, chromatin remodelers, and hi-
stone modifiers (5,15,22,29). In regard to CTCF acting as
a roadblock to AS of the archetypal CD45 gene, CTCF
has been directly linked to regulation of the three fac-
tors (RNAPII, DNMT-mediated methylation and TET-
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For example, besides its role in pausing RNAPII elonga-
tion, CTCF recruits and activates RNAPII when CTCF di-
rectly interacts with its largest subunit, POLR2A, via its C-
terminal domain (58). In addition, CTCF also binds to and
activates poly(ADP-ribose) polymerase (PARP1), which in-
activates DNA methyltransferase DNMT1 and thereby in-
hibits DNA methylation at CTCF binding sites (60,61).
Moreover, CTCF physically interacts with active TET en-
zymes and promotes DNA demethylation at specific sites
(62). The upstream regulatory effects of CTCF on these pro-
teins could add further complexity to the ‘roadblock’ model
(33,34), particularly in the context of their possible recruit-
ment at a genome-wide level. Therefore, the consequences
of this regulatory network on modulating AS demands fur-
ther experimental verification.
The CTCF-PARP1 regulatory axis
An additional role for CTCF in modulating AS could be
established from its known effect on activating PARP1 and
its poly(ADP-ribosyl)ation (PARylation) activity (60,61).
PARylation is a post-translational modification which is
catalyzed by active PARP enzymes transferring ADP-ribose
moieties from nicotinamide adenine dinucleotide (NAD+)
to specific amino acid residues on the target substrate
(63,64). It maintains various biological processes including
genomic stability, chromatin architecture, transcriptional
regulation, mitosis and cell death (64,65). While CTCF-
regulated PARP1-PARylation activity has not been veri-
fied yet, inhibition of PARP1 expression or its PARylation
activity has been linked to AS regulation. This has been
demonstrated via PARP1-nucleosome interactions at tar-
get exon/intron boundaries or PARylation-mediated regu-
lation of splicing factors including recruitment of spliceo-
somal factor 3B subunit 1 (SF3B1), a U2 snRNP (small nu-
clear ribonucleoprotein) spliceosomal member (66). A fol-
low up study found that RNAPII elongation rate was also
modulated at these sites depending on chromatin structure,
which is disrupted upon PARP1 depletion (67). PARP1,
in addition to its role as a PARylation activator, has been
linked to regulation of transcription and AS via mul-
tiple mechanisms involving chromatin modulation, tran-
scriptional modulation, post-transcriptional regulation of
RNA-binding proteins and mRNA stabilization (reviewed
in (68,69)). While this is true, possible roles for CTCF in
the regulation of AS via activating PARP1 and PARylation
will reveal new aspects of AS regulatory mechanisms, which
require further investigation (Figure 2B).
Given its direct effect on PARP1 and its PARylation ac-
tivity (60,61), CTCF might possibly regulate AS via RNA-
binding proteins, whose binding, recruitment and expres-
sion are directly regulated by PARP1 and/or PARylation
(68) (Figure 2B and C). This could be tested by examin-
ing the effect of CTCF on PARP1-mediated recruitment
of SF3B1 and subsequently pre-mRNA splicing (66). Pro-
teomics analysis of CTCF-interacting partners in MCF10A
cells identified RNA-binding proteins including snRNPs,
heterogeneous nuclear ribonucleoproteins (hnRNPs) and
serine-arginine proteins (70), which are essential compo-
nents of the splicing machinery (51). In addition, CTCF
can transcriptionally regulate or directly interact with mul-
tiple splicing factors. For instance, the interaction between
CTCF and POLR2A activates RNAPII (58), which pro-
vides a platform for factors regulating transcription initi-
ation, elongation and termination as well as RNA process-
ing (71). CTCF was also found to accumulate at specific
RNAPII termination sites on protein-coding and small nu-
clear RNA (snRNA) genes (72).
A study focused on CTCF-RNAPII dynamics showed
that CTCF regulated RNAPII elongation at the early elon-
gation checkpoint of c-myc, and RNAPII termination at
U2 snRNA gene via regulating the recruitment or activa-
tion of key factors, such as DRB-sensitivity-inducing fac-
tor (DSIF) and negative elongation factor (NELF) (42).
Moreover, CTCF interacts with and recruits positive tran-
scription elongation factor-b (P-TEFb) which stimulates
transcriptional elongation by phosphorylating POLR2A,
NELF and DSIF (42). The working model at the c-myc
site depends on CTCF binding downstream of the c-myc
promoter and recruitment of DSIF to stall RNAPII elon-
gation followed by P-TEFb recruitment which elicits con-
tinuing RNAPII elongation and RNA processing (42).
Whether CTCF modulates AS at this and other genomic
sites via this working model still awaits investigation. To-
gether, the direct effect of CTCF on RNAPII elongation,
PARP1/PARylation activity and splicing factor recruit-
ment support the notion that CTCF can modulate AS
via co-transcriptional regulation. Characterization of more
splicing factors, methylation regulators and other AS fac-
tors directly or indirectly regulated by CTCF will contribute
to our understanding of the complex mechanisms by which
CTCF modulates AS.
GENOMIC FEATURES
A regulatory framework for splicing provided by CTCF-
mediated chromatin architecture
Intragenic CTCF binding sites, particularly those proximal
to splice junctions, influence pre-mRNA splicing decisions,
and thus mediate alternative exon or intron inclusion (33–
38,40–42,44). Chromatin looping is a genome-wide func-
tion of CTCF placing it at the center of 3D chromatin archi-
tecture. Moreover, it brings genomic loci into spatial prox-
imity allowing CTCF to modulate gene expression (30–32).
The analysis of ChIP-seq, RNA-seq and high-throughput
chromosome conformation capture (Hi-C) data have re-
vealed the widespread formation of CTCF-mediated chro-
matin loops between promotors and intragenic regions (44).
Interestingly, chromatin loops formed upstream of exons in-
duced their inclusion by bringing these alternatively spliced
exons into physical proximity of the gene promoter (Figure
3A). This particular study provides a putative genome-wide
link between intragenic CTCF-mediated chromatin looping
and AS regulation (44).
Such a phenomenon affects members of the proto-
cadherin Pcdh gene family, which encode multiple iso-
forms responsible for neuronal cell surface diversity (36,37).
CTCF in conjunction with the cohesin complex mediates
DNA looping between Pcdh enhancers and active isoform-
specific promoters which induces alternatively spliced iso-
forms in a methylation-dependent manner (36,37). Muta-
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Figure 3. CTCF-mediated genomic and epigenetic regulation of alternative splicing. Schematic representation of putative genomic roles for CTCF in AS.
(A) Formation of chromatin loops to bring alternatively spliced exons into physical proximity of the gene promoter (44). (B) Nucleosome occupancy-
mediated altering of RNAPII elongation rate. (C) DNA methylation differentially regulates AS by CTCF and MeCP2. Unmethylated CpGs within CTCF
sites promote exon inclusion via CTCF binding while DNA methylation favors exon inclusion via MeCP2 binding (38).
mal regions abolishes CTCF binding in vitro. Furthermore,
CTCF knockdown leads to a reduction in CTCF binding
as well as the cohesin complex subunits RAD21 and SMC1
recruitment/binding and subsequently chromatin looping-
mediated enhancer/promoter communications (36). The
latter was also observed by RAD21 knockdown, which
showed no effect on CTCF binding (36,37). Despite the di-
rect link between CTCF/cohesin-mediated DNA looping
and modulation of Pcdh isoforms, the exact underlying AS
regulatory mechanism and downstream physiological con-
sequences are yet to be elucidated.
RNAPII elongation is prone to stalling at specific
CTCF/cohesin sites (35,40,73). This leaves open the pos-
sibility that CTCF might regulate AS via integrating chro-
matin looping and co-transcriptional factors. While CTCF-
mediated RNAPII stalling has been verified (33–35,42), co-
hesin has been found to be recruited to sites where RNAPII
pausing occurs, particularly when associated with CTCF
(40,74). The CTCF/cohesin complex downstream of the
PUMA and p21 promoters has been shown to stall RNAPII
elongation and regulate their expression (35). Similar to
CTCF-mediated Pcdh isoform regulation (36,37), knock-
down of CTCF abrogates CTCF binding at the PUMA and
p21 promoters and reduces cohesin complex (RAD21 and
SMC1) levels (35). Likewise, CTCF-mediated cohesin re-
cruitment and chromatin looping hinders RNAPII elonga-
tion downstream of proximal poly(A) sites in a methylation-
dependent manner. This links CTCF to pre-mRNA alterna-
tive polyadenylation (40), a process allowing usage of alter-
native poly(A) sites to produce multiple mRNA transcripts
from an individual gene (reviewed in (75)). Knowing that
CTCF recruits cohesin to sites where RNAPII pausing oc-
curs (35,40,73), it is possible that CTCF-mediated RNAPII
elongation stalling induces cohesin recruitment and thereby
chromatin looping, which leads to AS. Indeed, these find-
ings highlight a new role of CTCF-mediated 3D chromatin
organization in AS regulation. Conversely, CTCF-mediated
AS might also itself be involved in shaping the genome.
A role for CTCF-anchored nucleosomal occupancy
Nucleosome positioning is known to modulate RNAPII ki-
netics by acting as a physical barrier hindering RNAPII
elongation and thus promoting the recognition of exon-
intron boundaries by the splicing machinery (76). Nucle-
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introns or alternatively spliced exons, highlighting a role for
nucleosome positioning in exon definition (77–80). Further-
more, nucleosome occupancy has been correlated with reg-
ulating AS, specifically exon inclusion (78–80) and intron
retention (81). Exon-associated nucleosomes are enriched
in active H3K36me3 and repressive H3K27me2 histone
modifications, which help demarcate exon-intron bound-
aries (77,82). H3K36me3 is particularly enriched at actively
transcribed genes (82) and associated with different splic-
ing decisions involving recruitment of splicing regulators in
a context-dependent manner (83,84).
Interestingly, several studies have reported an enrichment
of CTCF sites around nucleosomes genome-wide, indicat-
ing that CTCF acts as an anchor for positioning nucleo-
somes in a symmetrical distribution (7,85–87). Yet, it is still
unknown whether CTCF binds proximal to well-positioned
nucleosomes or whether these nucleosomes are positioned
depending on CTCF binding. SNF2H, the ATPase sub-
unit of the ISWI chromatin remodeler, was found to be es-
sential for global organization of nucleosomes and TAD
formation via promoting CTCF binding. Knockdown of
SNF2H causes a genome-wide reduction in CTCF bind-
ing but without affecting its abundance (88). Furthermore,
CTCF was identified as an interacting partner of BRG1,
the ATPase subunit of the chromatin remodeling complex
SWI/SNF (89). While BRG1 depletion has no effect on ge-
nomic CTCF binding (88), it results in reduced nucleosome
occupancy around CTCF sites (90). Moreover, knowing
that PARylation mediates chromatin decondensation (65),
CTCF-activated PARylation can possibly alter RNAPII dy-
namics via chromatin relaxation (Figure 2B). Taken to-
gether, it would be interesting to examine how CTCF and
nucleosome positioning alters RNAPII elongation and sub-
sequently AS (Figure 3B). Nucleosome positioning is per-
haps the least studied mechanism linked to CTCF-mediated
AS, which warrants further experimental investigation.
EPIGENETIC FACTORS
Impact of DNA methylation on CTCF occupancy
Constitutive splicing depends on many factors including
the guanine and cytosine (GC) content, which is higher in
exons compared to introns. DNA methylation contributes
to the definition of exon-intron splice sites depending on
the enrichment of CpG dinucleotides within the spliced
exons/introns (91,92). It has been shown that 40% of
variable CTCF occupancy is linked to differential CpG
methylation, concentrated at two main positions within the
canonical CTCF consensus sequence (93). Methylation of
CpGs within CTCF target sites can prevent CTCF binding
(94–98), which has been found to be correlated with DNA
methylation patterns in a tissue-specific manner (93). The
interplay between CTCF and DNA methylation in modu-
lating AS has been described at a genome-wide or individual
transcript level (36–41,43,45).
Genome-wide methylation profiling of multiple tissues
could reveal an association between DNA methylation and
alternatively spliced transcripts (43). This is interesting,
given that CTCF binding sites often occur in GC-rich re-
gions, typically in CpG islands (8,99). These transcripts
were highly enriched in CTCF binding motifs and mutu-
ally exclusive exons in a position-dependent context (43).
As an exemplar, CTCF was found to regulate a pair of
mutually exclusive exons observed in synaptic calcium ion
channel Cacna1b transcription, where CTCF binding to hy-
pomethylated exon 37a (but not 37b) promotes its recog-
nition and inclusion in neurons (41). Methylation of the
exon 37a locus, on the other hand, leads to the inhibition
of CTCF binding and exon 37b inclusion. The resulting
Cacna1b isoform alters the calcium ion channel plasticity of
the neuron (41). However, the mechanism by which CTCF
modulates splicing at these sites has not been fully explored.
Learning from BDNF: an exemplar of CTCF-regulated AS
CTCF is important for exon inclusion by pausing RNAPII-
mediated transcription in a methylation-dependent man-
ner (33,34). However, in one archetypal example, CTCF
binding is required to protect against mis-splicing in
brain-derived neurotrophic factor (BDNF), in a seem-
ingly RNAPII elongation-independent manner (38). Mam-
malian BDNF, which is essential for regulating neurogen-
esis, synaptic plasticity, learning, memory and cognition,
encodes multiple transcripts generated by AS (100,101). In
turtle brain, intra-exonic splicing of BDNF causes a 40 bp
deletion wholly within the protein coding exon IV, gener-
ating the functionally distinct BDNF2a isoform which has
a 13 amino acid deletion and a truncated out-of-frame 21
amino acid C-terminus (102). When methyl-CpG-binding
protein MeCP2 binds to its cognate site upstream of the
BDNF intra-exonic splice site, it recruits the splicing factor
Y-box binding protein (YB-1), and generates this truncated
BDNF2a isoform. Interestingly, TET1 binding at MeCP2
sites was also essential for BDNF splicing, which is inhib-
ited by knockdown of MeCP2, YB1 or TET1 (38).
Moreover, suppression of the TET1-MeCP2-YB1 com-
plex, using a neural correlate of a classical conditioning
process in turtles, induces site-specific DNA demethylation
which primes CTCF binding to BDNF, proximal to the al-
ternatively spliced locus. This interaction leads to shielding
of canonical BDNF splicing and inhibition of its trunca-
tion, without RNAPII elongation stalling (38). The methy-
lation status within the BDNF promoter region appears
to govern the BDNF splicing decision. While methylated
CpG dinucleotides provide docking sites for MeCP2 bind-
ing, DNA demethylation dissociates MeCP2 and promotes
CTCF binding (38). Similarly, DNMT inhibition-mediated
hypomethylation in turtle or intracellular NAD biosynthe-
sis inhibition-regulated DNA hypermethylation in mouse,
both modulate BDNF transcription via triggering dissocia-
tion of MeCP2 or CTCF, respectively, from the BDNF pro-
moter region (39,103). In addition, NAD-depleted mouse
cortical neurons have decreased cohesin recruitment and
binding to the BDNF promoter, indicating a relationship
between chromatin structure and BDNF transcription (39).
Using hippocampal-specific depletion of CTCF in mice,
CTCF/cohesin binding proximal to the BDNF promoter
was also observed upon fear-conditioning. This attenu-
ated their learning and memory activities as well as expres-
sion of key learning-related genes including BDNF, Arc,
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CTCF and the TET1-MeCP2-YB1 complex in modulat-
ing BDNF splicing is influenced by chromatin structure and
their functional impact remains to be elucidated.
DNA methylation governs CTCF/MeCP2/TET1 interplay
Since MeCP2 is known for its role in regulating
methylation-dependent AS (38,105,106), the link be-
tween CTCF and MeCP2 may help reveal an important
underlying mechanism of CTCF-mediated AS. DNA
methylation mediates opposing effects on the role of
CTCF and MeCP2 binding to DNA and subsequently
regulation of pre-mRNA splicing (Figure 3C). Apart
from MeCP2/CTCF-mediated BDNF splicing (38), both
MeCP2 and CTCF can promote exon inclusion in a
context-dependent manner by binding to methylated or
unmethylated DNA, respectively (33,34,105). Conversely,
exon exclusion could occur via DNA demethylation
or methylation inhibiting MeCP2 or CTCF binding,
respectively. Both CTCF- and MeCP2-mediated exon
inclusion have been linked to modulating RNAPII kinetics
(33,34,105). While CTCF physically blocks RNAPII
elongation (33,34), MeCP2-mediated pausing of RNAPII
elongation is linked to recruiting histone deacetylase
(HDAC) activity and inducing histone hypoacetylation
(105), the inhibition of which increases the RNAPII
elongation rate and subsequently exon exclusion (107).
In addition, the DNA- and RNA-binding protein YB-1
physically interacts with both CTCF (108,109) and MeCP2
(38,110,111). While MeCP2-mediated recruitment of YB-1
has been linked to AS (38,111), the impact of CTCF and
YB-1 interaction on pre-mRNA splicing has not been
verified yet.
TET1 is another mutual interacting partner of CTCF
(62) and MeCP2 (103,112), through which it regulates AS
(33,34,38). Knowing that MeCP2 protects methylated 5mC
from TET1-mediated oxidation (113), it is not very clear
how abolishing MeCP2 binding to BDNF reduces TET1-
catalyzed demethylation during the conditioning process,
yet promotes CTCF binding (38). This could be explained
by the notion that MeCP2 and TET1 are binding part-
ners (103,112), implying that dissociation of MeCP2 pos-
sibly removes the whole TET1-MeCP2-YB1 complex. Al-
ternatively, TET1 dissociation might be compensated by
TET3, whose binding to BDNF has been found to in-
crease following conditioning (38), and important for
learning-dependent gene expression and behavioral adapta-
tion (114). Given the common factors acting in CTCF- and
MeCP2-mediated AS, their combined or independent roles
on modulating AS are still poorly understood and require
further studies particularly at a genome-wide level.
Lessons from CTCF haploinsufficiency in human and mouse
While CTCF binding is inhibited by DNA methylation (94–
98), CTCF itself regulates DNA methylation and preserves
methylation-free regions throughout the genome (115–117).
Moreover, CTCF knockdown induces global hypermethy-
lation, particularly at CTCF binding sites, as well as loss of
CTCF binding associated with altered expression of CTCF-
regulated genes (118). Interestingly, two individuals with
an intellectual disability and diagnosed with CTCF het-
erozygous deletions exhibited hypermethylation at nearly
300 CTCF binding sites genome-wide (119). The regulation
of genome-wide methylation by CTCF was also demon-
strated in Ctcf hemizygous mice, which are an ideal model of
Ctcf haploinsufficiency. Ctcf haploinsufficient mice exhibit
aberrant hypermethylation and increased spontaneous tu-
mor formation within various organs (120). Using a similar
model, we recently examined the effect of Ctcf haploinsuf-
ficiency on differential AS in several mouse tissues includ-
ing brain, kidney, liver, muscle and spleen (45). Our anal-
ysis showed an overall perturbation of the AS landscape,
causing mostly exon skipping, in a tissue-specific manner.
This was despite Ctcf dosage only decreasing less than 40%
in most tissues examined (45). We also detected a signif-
icant tissue-specific increase in intron retention events in
Ctcf haploinsufficient liver and kidney, primarily affecting
short introns with high GC content. The intron retention
events in the liver showed that Ctcf-mediated intron reten-
tion has a differing impact on the mRNA expression of the
intron-retaining genes. Interestingly, there was enrichment
of Ctcf binding sites proximal, particularly upstream, to the
majority of the differentially retained introns in mouse liver
(45).
Knowing that Ctcf haploinsufficiency (119,120) or
knockdown (118) induces hypermethylation, we proposed
that Ctcf haploinsufficiency increased intron retention
through a methylation-dependent mechanism (45), which
may involve altering the kinetics of RNAPII elongation or
chromatin looping. However, this hypothesis requires fur-
ther direct experimental validation, considering possible in-
direct effects of decreased Ctcf levels. To account for these
effects, it would be useful to examine the direct effect of
CTCF depletion on global AS by using the auxin-inducible
degron system. The degron system has been successfully
used to study the acute and reversible effect of CTCF de-
pletion on TAD boundaries and chromatin looping as well
as gene expression (121–123). In addition, mutating CTCF
binding sites using genome editing could provide another
experimental approach to study CTCF-mediated AS at the
individual transcript level. Given the cell-type-specific ef-
fects of CTCF on AS (45), further investigations into the
specific mechanism are required.
A chromatin code enriching AS regulation
Genome-wide chromatin-dependent regulation of AS
involves association of CTCF, HP1 and histone mod-
ifications (46). The heterochromatin protein (HP1)
family members (,  and  ), which can co-localize
with the heterochromatin-associated histone modification
H3K9me3, have been shown to regulate the impact of
DNA methylation on AS in a position-dependent manner.
Binding of HP1 to an exon or its upstream intron was
associated with diminishing or enhancing exon inclusion,
respectively. This methylation-dependent binding modu-
lates RNA splicing by recruiting splicing factors, such as
SRSF3, to the methylated site (124). Yet, it remains to
be determined how changing HP1 binding sites leads to
different AS decisions. A proposed ‘chromatin code’ high-
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gene silencer Argonaute (AGO1), RNAPII and select his-
tone marks around AS-regulated exons governs different
modes of exon inclusion or skipping (46). The interaction
of RNAPII with AGO1 (125) affects its elongation in
the context of HP1-mediated chromatin condensation
thus causing higher inclusion of alternative exons (126).
Knowing that HP1 recruits and interacts with CTCF
(127), it would be reasonable to postulate that AS can
result from crosstalk between HP1 and CTCF. In addition,
given the association between CTCF and HP1 proximal
to included exons (46), it would be interesting to further
explore whether CTCF binding contributes to altering
exon splicing decisions. This might be facilitated by DNA
methylation and HP1-mediated splicing factor recruitment
(124) (Figure 2C). Alternatively, CTCF may modulate
AS by slowing RNAPII elongation via HP1-mediated
chromatin condensation at methylated sites (128).
The distribution of CTCF binding sites coincides with
nucleosome positioning (7,85–87). These studies demon-
strated that enrichment of CTCF binding sites is de-
tected around nucleosomes associated with histone variants
H2A.Z and H3.3 and multiple histone modifications. The
co-localization of CTCF with these histone variants and
modifications marks the boundaries of histone methylation
domains and was linked to chromatin-mediated gene ex-
pression regulation (7,85–87). Consistent with the above,
CTCF binding along with active histone modifications
H3K9ac, H3K27ac or H3K4me3 have been shown to be
highly enriched in ‘more-included’ exons compared to ‘less-
included’ exons (129). However, correlations between the re-
pressive histone modifications H3K27me3 and H3K9me2
and CTCF binding sites have been detected around al-
ternatively skipped exons in MCF7 more than MCF10A
cells (46). For example, the PUMA locus harbors an intra-
genic chromatin boundary consisting of the active marks
H3K4me3 and H3K9ac and the repressive mark H3K9me3,
important for CTCF-mediated regulation of PUMA (35).
Interestingly, CTCF knockdown reduces H3K9me3 levels
within PUMA as well as at p21 loci (35). Moreover, a broad
putative role for CTCF in regulating diverse histone modifi-
cations could be achieved via PARP1 and PARylation (65).
These findings argue for a plausible link between CTCF-
associated histone modifications and pre-mRNA splicing
outcome, which might involve regulation of RNAPII ki-
netics and/or splicing factor recruitment via chromatin-
binding proteins.
CONCLUDING REMARKS AND FUTURE DIREC-
TIONS
Transcriptomic diversity is governed by AS, which is orches-
trated by complex regulatory mechanisms comprising ge-
nomic, epigenetic, and transcriptional layers (51,130). The
versatile and ubiquitous factor CTCF plays diverse roles
in these regulatory layers through multimodal mechanisms.
However, there are still gaps in our understanding of the in-
terplay between these mechanisms. Further research is re-
quired to gain a clearer picture of the CTCF-mediated AS
regulatory network. Combined computational and experi-
mental efforts are required to foster a comprehensive mech-
anistic understanding of the experimentally verified and pu-
tative AS regulatory roles mediated by CTCF (Table 1).
Overall, most evidence of CTCF-mediated AS regulation
has been found at the individual transcript level while the
putative roles are mostly described at a genome-wide level.
Enrichment of CTCF binding sites proximal to alter-
natively spliced exons has been linked to methylation,
RNAPII elongation, chromatin looping, histone modifi-
cations and splicing factor recruitment (33–46). To date,
most studies have examined RNAPII elongation- and DNA
methylation-related mechanisms. However, other CTCF-
mediated mechanisms regulating AS, particularly nucleo-
some positioning, chromatin architecture and histone mod-
ifications, remain largely uncharacterized. While CTCF ap-
pears to spatio-temporally coordinate AS, it is still un-
known whether these factors have cooperative, competi-
tive, dependent, or independent relationships in CTCF-
mediated AS. In addition, the extent of CTCF’s role in mod-
ulating AS remains uncertain in regard to its specificity to
individual transcripts versus genome-wide levels, ubiqui-
tous versus cell-type-specific CTCF target sites and cellu-
lar versus systemic functions. It is worth noting that the as-
sociation of CTCF-mediated AS events and resulting bio-
logical functions have not been extensively studied. Some
studies have already shed light on several functions influ-
enced by this role such as lymphocyte development (33,34),
p53-mediated apoptotic response (35), learning-dependent
activities (38), neuronal cell surface diversity (36), calcium
ion channel plasticity (41) and the impact of Ctcf haploin-
sufficiency (45).
Pursuing these avenues of research present many com-
putational challenges including the complexities of analyz-
ing the transcriptome and epigenome as well as current
limitations of the available bioinformatic tools in detecting
AS events, annotating protein isoforms and providing opti-
mal data resolution and coverage (reviewed in (131,132)).
There are several data resources, such as ENCODE (en-
codeproject.org), the Cancer Genome Atlas (TCGA: https:
//www.cancer.gov/tcga), and the Cancer Cell Line Encyclo-
pedia (portals.broadinstitute.org/ccle), which are useful for
comprehensive analysis of AS landscapes in various nor-
mal and malignant cells. Given frequent allelic variations
and somatic mutations in CTCF (133–136), it would be im-
portant to establish links between aberrant CTCF-mediated
AS and cancer. Knowing that CTCF and its testis-specific
paralogue CTCF-like (CTCFL)/BORIS have some mutual
genomic occupancy (137), a new role for BORIS in AS regu-
lation may also warrant further investigation. Comprehen-
sive data analyses should aim to resolve the reciprocal and
mutually exclusive interplay between CTCF and key fac-
tors involved in AS regulation rather than studying CTCF-
mediated effects on an individual factor.
Structural changes in the genome arising from genetic
variation or introduced experimentally via deletion or in-
version of CTCF sites using genome editing can have patho-
logical consequences. Disrupting the highly conserved ar-
chitecture of TADs has been shown to have a dramatic
impact on development and normal spatio-temporal con-
trol of gene expression (138–140). While the impact of ge-
netic variation on CTCF-mediated chromatin looping has
been well established (138–140), the consequences for the
AS landscape is only now being revealed. Allelic variation
at CTCF sites adjacent to exons can both affect CTCF bind-
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Table 1. Summary of the known mechanisms of CTCF in modulating alternative splicing. CTCF-mediated AS regulatory mechanisms are divided into
verified or putative roles




CD45 Human Burkitt lymphoma B cells CTCF binding to CD45 exon 5







PUMA, p21 Human HCT116 colorectal
carcinoma cells
CTCF binding recruits cohesin
downstream to PUMA and p21
promoters, which stalls RNAPII





DNA methylation BDNF Turtle brain tissue, mouse embryonic
cortical neurons
CTCF binding to unmethylated target






DNA methylation Cacna1b F11 (rat dorsal-root ganglion
neurons/mouse neuroblastoma
hybrid) cells
CTCF binding to hypomethylated sites







Pcdh Human SK-N-SH and mouse N2a

























HeLa cells CTCF controls RNAPII elongation
and termination via recruitment of





Genome-wide Human Burkitt lymphoma B cells Association between CTCF and





Genome-wide Various cells Association between CTCF binding
and RNAPII stalling at specific sites
- (58,59)
DNA methylation Genome-wide Mouse retina and brain tissues Association of CTCF binding sites





Genome-wide Human lymphoblastoid cells CTCF-mediated chromatin loops
bring alternatively spliced exons into
physical proximity of gene promoter
- (44)
DNA methylation Genome-wide Mouse brain, kidney, liver, muscle
and spleen tissues
Ctcf haploinsufficiency mediates
tissue-specific changes in AS events,
notably an increase in intron retention





Genome-wide Various cells Association between CTCF
binding and histone modifications
close to alternatively spliced exons
- (35,46,129)
Miscellaneous Genome-wide Human MCF7 breast cancer cells
Non-tumorigenic MCF10A
mammary cells
Association between CTCF and HP1
proximal to included exons which may
involve splicing factor recruitment
- (46)
Miscellaneous* Genome-wide Various cells CTCF-mediated activation of PARP1
and PARylation govern AS via
hypomethylation of CTCF binding
sites, RNAPII elongation, chromatin
relaxation and splicing factor
recruitment
- (60,61,66–69)
*denotes involvement of methylation-regulated CTCF sites.
explore correlations between transcriptomic and genomic
data and cellular or developmental phenotypes. Moreover,
given the extensive characterization of CTCF as a tumor
suppressor gene (120,136,141–143), its frequent mutation in
cancer (133,134,136) and loss- or gain-of-function pheno-
types (135), causal links between CTCF-mediated aberrant
AS and cancer are likely to emerge (144,145).
To date, the role of CTCF in AS has been mostly eluci-
dated using computational approaches, while experimental
validation remains challenging especially at a genome-wide
level. This is further complicated by the fact that CTCF
is essential for somatic cell viability (143), genome archi-
tecture (30,32) and gene expression regulation (5,22). In-
tegrating the known roles for CTCF in regulating chro-
matin architecture and gene expression with AS-mediated
effects on transcriptome and proteome diversity would pro-
vide opportunities for future directions. For instance, it
is still unknown how AS is impacted by CTCF-mediated
TADs and compartmentalization of chromatin. In addi-
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key AS-regulating genes and interact directly with proteins
and RNA molecules leading to direct or indirect effects on
AS. Ultimately, unravelling the underlying mechanisms by
which CTCF regulates AS may address the question as to
what determines the fates of CTCF-mediated alternatively
spliced transcripts and their biological functions.
FUNDING
National Health and Medical Research Council [Project
grants 1128748 and 1128175 to J.E.J.R., Investigator grants
to J.E.J.R. 1177305 and to U.S. 1196405]; Tour de Cure
(Scott Canner Research Fellowship to C.G.B. and for re-
search grants to C.G.B. and J.E.J.R.]; Tour de Rocks project
support (to C.G.B.); Cancer Council NSW project grants
[RG11-12, RG14-09 to J.E.J.R. and C.G.B., (RG20-12) to
U.S. and C.G.B.]; Cure the Future (to J.E.J.R.); U.S. was
supported via an Early Career Researcher Fellowship from
Cancer Institute New South Wales; A.B.A. is supported
by a PhD Scholarship from Umm Al-Qura University in
Saudi Arabia to conduct a PhD at The University of Syd-
ney. Funding for open access charge was supported by an
anonymous foundation.
Conflict of interest statement. None declared.
REFERENCES
1. Lobanenkov,V.V., Nicolas,R.H., Adler,V.V., Paterson,H.,
Klenova,E.M., Polotskaja,A.V. and Goodwin,G.H. (1990) A novel
sequence-specific DNA binding protein which interacts with three
regularly spaced direct repeats of the CCCTC-motif in the
5′-flanking sequence of the chicken c-myc gene. Oncogene, 5,
1743–1753.
2. Klenova,E.M., Nicolas,R.H., Paterson,H.F., Carne,A.F.,
Heath,C.M., Goodwin,G.H., Neiman,P.E. and Lobanenkov,V.V.
(1993) CTCF, a conserved nuclear factor required for optimal
transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger
protein differentially expressed in multiple forms. Mol. Cell. Biol.,
13, 7612–7624.
3. Bell,A.C., West,A.G. and Felsenfeld,G. (1999) The protein CTCF is
required for the enhancer blocking activity of vertebrate insulators.
Cell, 98, 387–396.
4. Filippova,G.N., Fagerlie,S., Klenova,E.M., Myers,C., Dehner,Y.,
Goodwin,G., Neiman,P.E., Collins,S.J. and Lobanenkov,V.V. (1996)
An exceptionally conserved transcriptional repressor, CTCF,
employs different combinations of zinc fingers to bind diverged
promoter sequences of avian and mammalian c-myc oncogenes.
Mol. Cell. Biol., 16, 2802–2813.
5. Ohlsson,R., Renkawitz,R. and Lobanenkov,V. (2001) CTCF is a
uniquely versatile transcription regulator linked to epigenetics and
disease. Trends Genet., 17, 520–527.
6. Kim,T.H., Abdullaev,Z.K., Smith,A.D., Ching,K.A.,
Loukinov,D.I., Green,R.D., Zhang,M.Q., Lobanenkov,V.V. and
Ren,B. (2007) Analysis of the vertebrate insulator protein
CTCF-binding sites in the human genome. Cell, 128, 1231–1245.
7. Cuddapah,S., Jothi,R., Schones,D.E., Roh,T.Y., Cui,K. and
Zhao,K. (2009) Global analysis of the insulator binding protein
CTCF in chromatin barrier regions reveals demarcation of active
and repressive domains. Genome Res., 19, 24–32.
8. Chen,H., Tian,Y., Shu,W., Bo,X. and Wang,S. (2012)
Comprehensive identification and annotation of cell type-specific
and ubiquitous CTCF-binding sites in the human genome. PLoS
One, 7, e41374.
9. Saldana-Meyer,R., Gonzalez-Buendia,E., Guerrero,G.,
Narendra,V., Bonasio,R., Recillas-Targa,F. and Reinberg,D. (2014)
CTCF regulates the human p53 gene through direct interaction with
its natural antisense transcript, Wrap53. Genes Dev., 28, 723–734.
10. Hansen,A.S., Hsieh,T.S., Cattoglio,C., Pustova,I.,
Saldaña-Meyer,R., Reinberg,D., Darzacq,X. and Tjian,R. (2019)
Distinct classes of chromatin loops revealed by deletion of an
RNA-binding region in CTCF. Mol. Cell, 76, 395–411.
11. Saldaña-Meyer,R., Rodriguez-Hernaez,J., Escobar,T., Nishana,M.,
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